US vs. Eu­rope: New re­search pa­per com­pares drug re­view times across bor­ders

The US boast­ed faster re­view times for drug ap­pli­ca­tions over the past decade com­pared to those in the EU and Switzer­land, ac­cord­ing to a new pa­per pub­lished Mon­day in the An­nals of In­ter­nal Med­i­cine.

The re­searchers as­sessed the length of reg­u­la­to­ry re­view times for both pri­ma­ry and sup­ple­men­tal in­di­ca­tions in the US and Eu­rope be­tween 2011 and 2020 as well as dif­fer­ences in sub­mis­sion times dur­ing that pe­ri­od. The re­searchers found that over­all, the me­di­an re­view time, from sub­mis­sion to ap­proval, was 39 weeks (about nine months) in the US com­pared with 44 weeks (about 10 months) in the EU and Switzer­land.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER